Vertex Pharmaceuticals Gestione
Gestione criteri di controllo 2/4
Vertex Pharmaceuticals Il CEO è Reshma Kewalramani, nominato in Apr2020, e ha un mandato di 4.58 anni. la retribuzione annua totale è $ 20.59M, composta da 7.3% di stipendio e 92.7% di bonus, comprese azioni e opzioni aziendali. possiede direttamente 0.029% delle azioni della società, per un valore di $ 33.94M. La durata media del mandato del team dirigenziale e del consiglio di amministrazione è rispettivamente 5.1 anni e 4.8 anni.
Informazioni chiave
Reshma Kewalramani
Amministratore delegato
US$20.6m
Compenso totale
| Percentuale dello stipendio del CEO | 7.3% |
| Mandato del CEO | 4.6yrs |
| Proprietà del CEO | 0.03% |
| Durata media del management | 5.1yrs |
| Durata media del Consiglio di amministrazione | 4.8yrs |
Aggiornamenti recenti sulla gestione
Recent updates
Vertex Pharmaceuticals: Strong Execution Continued In Q3 But The Valuation Reflects It
Nov 05Vertex Pharmaceuticals: The Future Looks Bright, But It May Be A Choppy Ride
Oct 18Vertex Joined The M&A Craze - Limited Upside Potential (Downgrade)
Oct 10Investors Are Underestimating The Potential Of Vertex's Non-Addictive Pain Drug
Sep 15Vertex Pharmaceuticals: Is The Recent Barclays Downgrade Justified? I'm Not Convinced
Sep 05Vertex Stock: Came For CF Drugs, Staying For Gene Therapy
Aug 02Is There An Opportunity With Vertex Pharmaceuticals Incorporated's (NASDAQ:VRTX) 28% Undervaluation?
Jul 11
Vertex: Strategic Diversification From Gene Therapy To Acute Pain Management
Jul 09If EPS Growth Is Important To You, Vertex Pharmaceuticals (NASDAQ:VRTX) Presents An Opportunity
Jun 20Vertex: New, Longer-Term Casgevy Data Makes Case For Blockbuster Sales
Jun 17Vertex: Like A Fine Wine, This Stock Seems To Get Better With Time
Jun 04Here's Why Shareholders Will Not Be Complaining About Vertex Pharmaceuticals Incorporated's (NASDAQ:VRTX) CEO Pay Packet
May 09Vertex Pharmaceuticals Incorporated Just Beat Analyst Forecasts, And Analysts Have Been Updating Their Predictions
May 08Vertex To Buy Alpine Immune - Why This Deal Feels Slightly 'Vanilla'
Apr 11Getting In Cheap On Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) Is Unlikely
Apr 05Vertex Pharmaceuticals: Diversifying Its Drug Portfolio For Future Growth
Mar 21Are Investors Undervaluing Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) By 35%?
Mar 15Vertex: One Of My All-Time Favorite Biotech Stocks Has More Room To Run
Feb 28We Like The Quality Of Vertex Pharmaceuticals' (NASDAQ:VRTX) Earnings
Feb 22Earnings Update: Here's Why Analysts Just Lifted Their Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) Price Target To US$452
Feb 07Vertex And Crispr: Second Casgevy Approval Pushes Revenue Potential Into Multi-Billion Dollar Range
Jan 22With EPS Growth And More, Vertex Pharmaceuticals (NASDAQ:VRTX) Makes An Interesting Case
Jan 15Risks To Shareholder Returns Are Elevated At These Prices For Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX)
Dec 25An Intrinsic Calculation For Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) Suggests It's 29% Undervalued
Nov 13With EPS Growth And More, Vertex Pharmaceuticals (NASDAQ:VRTX) Makes An Interesting Case
Oct 02Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) Shares Could Be 21% Below Their Intrinsic Value Estimate
Jul 31We Ran A Stock Scan For Earnings Growth And Vertex Pharmaceuticals (NASDAQ:VRTX) Passed With Ease
Jul 03Analisi delle retribuzioni degli amministratori delegati
| Data | Compenso totale | Stipendio | Guadagni aziendali |
|---|---|---|---|
| Sep 30 2024 | n/a | n/a | -US$480m |
| Jun 30 2024 | n/a | n/a | -US$490m |
| Mar 31 2024 | n/a | n/a | US$4b |
| Dec 31 2023 | US$21m | US$2m | US$4b |
| Sep 30 2023 | n/a | n/a | US$3b |
| Jun 30 2023 | n/a | n/a | US$3b |
| Mar 31 2023 | n/a | n/a | US$3b |
| Dec 31 2022 | US$16m | US$1m | US$3b |
| Sep 30 2022 | n/a | n/a | US$3b |
| Jun 30 2022 | n/a | n/a | US$3b |
| Mar 31 2022 | n/a | n/a | US$2b |
| Dec 31 2021 | US$15m | US$1m | US$2b |
| Sep 30 2021 | n/a | n/a | US$2b |
| Jun 30 2021 | n/a | n/a | US$2b |
| Mar 31 2021 | n/a | n/a | US$3b |
| Dec 31 2020 | US$9m | US$1m | US$3b |
| Sep 30 2020 | n/a | n/a | US$3b |
| Jun 30 2020 | n/a | n/a | US$2b |
| Mar 31 2020 | n/a | n/a | US$2b |
| Dec 31 2019 | US$7m | US$702k | US$1b |
Compensazione vs Mercato: La retribuzione totale di Reshma ($USD 20.59M ) è superiore alla media delle aziende di dimensioni simili nel mercato US ($USD 12.73M ).
Compensazione vs guadagni: La retribuzione di Reshma è aumentata nonostante l'azienda non sia redditizia.
AMMINISTRATORE DELEGATO
Reshma Kewalramani (51 yo)
4.6yrs
Mandato
US$20,594,441
Compensazione
Dr. Reshma Kewalramani, M.D., FASN, is Director at Year Up Inc. since September 2023. She had been an Independent Director of Ginkgo Bioworks Holdings, Inc. (formerly known as Ginkgo Bioworks, Inc.) since...
Gruppo dirigente
| Nome | Posizione | Mandato | Compensazione | Proprietà |
|---|---|---|---|---|
| Executive Chairman | 15.3yrs | US$6.60m | 0.0040% $ 4.7m | |
| CEO, President & Director | 4.6yrs | US$20.59m | 0.029% $ 33.9m | |
| Executive VP & CFO | 5.6yrs | US$7.37m | 0.017% $ 19.8m | |
| Executive VP & COO | 3.3yrs | US$9.00m | 0.019% $ 22.3m | |
| Executive VP & Chief Scientific Officer | 9.8yrs | US$6.54m | 0.010% $ 11.6m | |
| Senior VP & Chief Accounting Officer | 3.5yrs | Nessun dato | 0.0029% $ 3.4m | |
| SVP and Chief Information & Data Officer | 5.8yrs | Nessun dato | Nessun dato | |
| Senior Vice President of Investor Relations | 2.2yrs | Nessun dato | Nessun dato | |
| Executive VP & Chief Legal Officer | 2.2yrs | Nessun dato | 0.0065% $ 7.5m | |
| Senior VP & Chief Communications Officer | 5.8yrs | Nessun dato | Nessun dato | |
| Senior VP & Chief Human Resources Officer | 7.3yrs | Nessun dato | Nessun dato | |
| Executive VP & Chief Patient and External Affairs Officer | 17.3yrs | US$6.20m | 0.023% $ 26.1m |
5.1yrs
Durata media
57yo
Età media
Gestione esperta: Il team dirigenziale di VRTX è esperto e expertise (durata media dell'incarico 5.1 anni).
Membri del Consiglio di amministrazione
| Nome | Posizione | Mandato | Compensazione | Proprietà |
|---|---|---|---|---|
| Executive Chairman | 15.3yrs | US$6.60m | 0.0040% $ 4.7m | |
| CEO, President & Director | 4.8yrs | US$20.59m | 0.029% $ 33.9m | |
| Lead Independent Director | 26.8yrs | US$600.04k | 0.016% $ 17.9m | |
| Independent Director | 7.4yrs | US$537.63k | 0.0023% $ 2.6m | |
| Independent Director | 5.8yrs | US$559.79k | 0.0021% $ 2.4m | |
| Independent Director | 9.4yrs | US$550.31k | 0.0013% $ 1.5m | |
| Independent Director | 1.1yrs | US$449.08k | Nessun dato | |
| Independent Director | 4.4yrs | US$553.11k | 0.00064% $ 738.4k | |
| Independent Director | 2.5yrs | US$544.66k | 0.00060% $ 692.3k | |
| Independent Director | less than a year | US$407.65k | Nessun dato | |
| Independent Director | less than a year | Nessun dato | Nessun dato |
4.8yrs
Durata media
59yo
Età media
Consiglio di amministrazione esperto: I membri del consiglio di amministrazione di VRTX sono considerati esperti (durata media dell'incarico 4.8 anni).